BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Launched by THERAS, INC., D/B/A BBOT (BRIDGEBIO ONCOLOGY THERAPEUTICS) · Apr 1, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called BBO-11818 for adults with certain types of cancer that have a specific genetic mutation known as KRAS. The trial is looking at the safety of this treatment and how well it might work in patients with advanced cancers like non-small cell lung cancer, pancreatic cancer, and colorectal cancer. To participate, patients need to have a documented diagnosis of these cancers with specific KRAS mutations. They should also be in fairly good health, as determined by their performance status, and their cancer should be measurable according to specific criteria.

If someone is eligible and decides to join the study, they will receive the treatment and be monitored closely for any side effects or changes in their condition. This trial is currently recruiting participants, so there’s an opportunity for patients who meet the criteria to take part in this research and potentially benefit from a new therapy aimed at fighting their cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation, or KRAS-amplification
• • Measurable disease by RECIST v1.1
• • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
• Exclusion Criteria:
• • Malignancy within the last 2 years as specified in the protocol
• • Untreated brain metastases
• • Known hypersensitivity to BBO-11818 or its excipients
• • Other inclusion/exclusion criteria are specified in the protocol.